Literature DB >> 11754355

Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals.

Simona Vertuani1, Martina Bazzaro, Guido Gualandi, Fabiola Micheletti, Mauro Marastoni, Cinzia Fortini, Alessandro Canella, Michele Marino, Roberto Tomatis, Serena Traniello, Riccardo Gavioli.   

Abstract

The majority of hepatitis C virus (HCV)-infected individuals fail to resolve the infection and become chronically infected despite the presence of HCV-specific CTL responses directed to different HCV-derived peptide antigens. Only a minority of individuals is able to clear the virus by mounting efficient CTL responses early after acute infection, but at present it is not clear whether viral clearance is associated with CTL responses of defined specificity. To elucidate those responses associated with improvement of the disease, we analyzed CTL responses to 16 different HLA-A2-presented, HCV-derived epitopes in 12 chronically infected patients, 14 chronically infected patients treated with interferon-alpha, and in one patient with acute symptomatic disease. We show here that the majority of chronically infected individuals present CTL responses directed to an NS4-derived peptide antigen (amino acids 1789-1797). Treated patients presented stronger HCV-specific CTL responses and therapy-induced changes in CTL target choice. In particular, 13 out of 14 individuals responded to an NS3-derived epitope (amino acids 1073-1081). By longitudinal analysis we show that five individuals responding to IFN-alpha therapy with decreases in alanine aminotransferase levels presented a strong CTL activity directed to the NS3-derived epitope. One patient that spontaneously resolved the infection presented a generally strong CTL activity specific for HCV-derived epitopes with a dominant response to the NS3-derived peptide antigen. This suggests that CTL responses directed to this NS3-derived antigen may be beneficial for the control of HCV infection. Improvement of these responses may represent a therapeutic intervention in chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11754355     DOI: 10.1002/1521-4141(200201)32:1<144::AID-IMMU144>3.0.CO;2-X

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  18 in total

Review 1.  Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

Authors:  Juan-Ramón Larrubia; Elia Moreno-Cubero; Joaquín Miquel; Eduardo Sanz-de-Villalobos
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C.

Authors:  Jian Wang; Gui-Ju Xiang; Bing-Xiang Liu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

3.  Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.

Authors:  Santa Olivera; Angel Perez; Viviana Falcon; Dioslaida Urquiza; Dagmara Pichardo; Gillian Martinez-Donato
Journal:  Arch Virol       Date:  2020-02-03       Impact factor: 2.574

4.  Interferon-gamma is produced by CD8 T cells in response to HLA-A24-restricted hepatitis C virus epitopes after sustained virus loss.

Authors:  K Kobayashi; M Ishii; M Shiina; Y Ueno; Y Kondo; A Kanno; Y Miyazaki; T Yamamoto; T Kobayashi; H Niitsuma; Y Kikumoto; H Takizawa; T Shimosegawa
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

5.  Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection.

Authors:  Nourredine Himoudi; Jean-Daniel Abraham; Anne Fournillier; Yu Chun Lone; Aurélie Joubert; Anne Op De Beeck; Delphine Freida; François Lemonnier; Marie Paule Kieny; Geneviève Inchauspé
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  Relation between viral fitness and immune escape within the hepatitis C virus protease.

Authors:  J Söderholm; G Ahlén; A Kaul; L Frelin; M Alheim; C Barnfield; P Liljeström; O Weiland; D R Milich; R Bartenschlager; M Sällberg
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

7.  Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains.

Authors:  Karina Yusim; Rebecca Dilan; Erica Borducchi; Kelly Stanley; Elena Giorgi; William Fischer; James Theiler; Joseph Marcotrigiano; Bette Korber; Dan H Barouch
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

8.  Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response.

Authors:  C Rollier; E Depla; J A R Drexhage; E J Verschoor; B E Verstrepen; A Fatmi; C Brinster; A Fournillier; J A Whelan; M Whelan; D Jacobs; G Maertens; G Inchauspé; J L Heeney
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial).

Authors:  Elena Chernykh; Olga Leplina; Ekaterina Oleynik; Marina Tikhonova; Tamara Tyrinova; Natalia Starostina; Alexandr Ostanin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

10.  Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.

Authors:  Natalia Lapteva; Melissa Aldrich; Lisa Rollins; Wenhong Ren; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.